Siegbahn A - Search Results

1

Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy.

James SK, Armstrong P, Barnathan E, Califf R, Lindahl B, Siegbahn A, Simoons ML, Topol EJ, Venge P, Wallentin L; GUSTO-IV-ACS Investigators. James SK, et al. Among authors: siegbahn a. J Am Coll Cardiol. 2003 Mar 19;41(6):916-24. doi: 10.1016/s0735-1097(02)02969-8. J Am Coll Cardiol. 2003. PMID: 12651034 Free article.

2

Coagulation and fibrinolysis during the normal menstrual cycle.

Siegbahn A, Odlind V, Hedner U, Venge P. Siegbahn A, et al. Ups J Med Sci. 1989;94(2):137-52. doi: 10.3109/03009738909178559. Ups J Med Sci. 1989. PMID: 2527430

3

Specific binding of B-CLL cell-derived chemokinetic inhibitory factor (CIF) to human polymorphonuclear leukocytes.

Siegbahn A, Garcia RC, Kishi K, Nilsson K, Venge P. Siegbahn A, et al. Eur J Haematol. 1987 Aug;39(2):172-9. doi: 10.1111/j.1600-0609.1987.tb00749.x. Eur J Haematol. 1987. PMID: 3666104

4

Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease.

Toss H, Lindahl B, Siegbahn A, Wallentin L. Toss H, et al. Among authors: siegbahn a. Circulation. 1997 Dec 16;96(12):4204-10. doi: 10.1161/01.cir.96.12.4204. Circulation. 1997. PMID: 9416883 Clinical Trial.

5

Low-molecular weight heparin reduces the generation and activity of thrombin in unstable coronary artery disease.

Ernofsson M, Strekerud F, Toss H, Abildgaard U, Wallentin L, Siegbahn A. Ernofsson M, et al. Among authors: siegbahn a. Thromb Haemost. 1998 Mar;79(3):491-4. Thromb Haemost. 1998. PMID: 9531028 Clinical Trial.

6

Increased fibrinogen levels are associated with persistent Chlamydia pneumoniae infection in unstable coronary artery disease.

Toss H, Gnarpe J, Gnarpe H, Siegbahn A, Lindahl B, Wallentin L. Toss H, et al. Among authors: siegbahn a. Eur Heart J. 1998 Apr;19(4):570-7. doi: 10.1053/euhj.1997.0771. Eur Heart J. 1998. PMID: 9597405

7

Influences of sex and smoking habits on anticoagulant activity in low-molecular-weight heparin treatment of unstable coronary artery disease.

Toss H, Wallentin L, Siegbahn A. Toss H, et al. Among authors: siegbahn a. Am Heart J. 1999 Jan;137(1):72-8. doi: 10.1016/s0002-8703(99)70461-8. Am Heart J. 1999. PMID: 9878938 Clinical Trial.

8

Low molecular weight heparin (dalteparin) as adjuvant treatment of thrombolysis in acute myocardial infarction--a pilot study: biochemical markers in acute coronary syndromes (BIOMACS II).

Frostfeldt G, Ahlberg G, Gustafsson G, Helmius G, Lindahl B, Nygren A, Siegbahn A, Swahn E, Venge P, Wallentin L. Frostfeldt G, et al. Among authors: siegbahn a. J Am Coll Cardiol. 1999 Mar;33(3):627-33. doi: 10.1016/s0735-1097(98)00612-3. J Am Coll Cardiol. 1999. PMID: 10080461 Free article. Clinical Trial.

9

The effect of a low molecular mass thrombin inhibitor, inogatran, and heparin on thrombin generation and fibrin turnover in patients with unstable coronary artery disease.

Linder R, Oldgren J, Egberg N, Grip L, Larson G, Siegbahn A, Wallentin L. Linder R, et al. Among authors: siegbahn a. Eur Heart J. 1999 Apr;20(7):506-18. doi: 10.1053/euhj.1998.1336. Eur Heart J. 1999. PMID: 10365287 Clinical Trial.

10

Activated partial thromboplastin time and clinical outcome after thrombin inhibition in unstable coronary artery disease.

Oldgren J, Linder R, Grip L, Siegbahn A, Wallentin L. Oldgren J, et al. Among authors: siegbahn a. Eur Heart J. 1999 Nov;20(22):1657-66. doi: 10.1053/euhj.1999.1750. Eur Heart J. 1999. PMID: 10543929 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

328 results

Search Page